Leerink Partnrs Has Negative Estimate for DSGN Q3 Earnings

Key Points

• Leerink Partners has reduced its earnings forecast for Design Therapeutics (DSGN) for Q3 2025 to ($0.35) per share, down from a prior estimate of ($0.33). The updated full-year earnings estimate stands at ($0.91) per share.
• As of now, Design Therapeutics' stock is priced at $5.16 with a market capitalization of $293.86 million. The stock has a fifty-two week range of $2.60 to $7.77.
• Institutional investors currently own 56.64% of Design Therapeutics' stock, with several firms, including ProShare Advisors LLC and Invesco Ltd., recently purchasing new stakes in the company.

Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) - Leerink Partnrs cut their Q3 2025 EPS estimates for Design Therapeutics in a research note issued to investors on Tuesday, August 12th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($0.35) per share for the quarter, down from their previous forecast of ($0.33). The consensus estimate for Design Therapeutics' current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Design Therapeutics' Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.35) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.45) EPS and FY2027 earnings at ($1.70) EPS.

Design Therapeutics Stock Down 5.3%

DSGN stock traded down $0.2730 during trading on Friday, hitting $4.8970. 25,935 shares of the company's stock traded hands, compared to its average volume of 133,253. Design Therapeutics has a 52 week low of $2.60 and a 52 week high of $7.77. The stock has a fifty day moving average price of $4.09 and a two-hundred day moving average price of $4.09. The stock has a market capitalization of $278.87 million, a price-to-earnings ratio of -4.36 and a beta of 1.58.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.02).

Hedge Funds Weigh In On Design Therapeutics

Several institutional investors have recently modified their holdings of the company. Bank of America Corp DE grew its position in Design Therapeutics by 11.1% in the 2nd quarter. Bank of America Corp DE now owns 24,625 shares of the company's stock valued at $83,000 after buying an additional 2,459 shares in the last quarter. Invesco Ltd. boosted its position in shares of Design Therapeutics by 26.8% during the 2nd quarter. Invesco Ltd. now owns 14,364 shares of the company's stock valued at $48,000 after purchasing an additional 3,033 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Design Therapeutics by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 761,640 shares of the company's stock valued at $4,700,000 after purchasing an additional 3,090 shares in the last quarter. MPM Bioimpact LLC lifted its stake in Design Therapeutics by 0.6% during the first quarter. MPM Bioimpact LLC now owns 562,943 shares of the company's stock valued at $2,173,000 after buying an additional 3,396 shares in the last quarter. Finally, Palumbo Wealth Management LLC lifted its stake in Design Therapeutics by 6.5% during the first quarter. Palumbo Wealth Management LLC now owns 58,278 shares of the company's stock valued at $225,000 after buying an additional 3,582 shares in the last quarter. Institutional investors own 56.64% of the company's stock.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.